ASX Share rice
Tue 11 Aug 2020 - 10:33:am (Sydney)

MDR Share Price

MEDADVISOR LIMITEDMDRHealth Care Equipment & Services

MDR Company Information

Name:

MedAdvisor Limited

Sector:

Healthcare

Industry:

Health Information Services

GIC Industry:

Health Care Technology

GIC Sub Industry:

Health Care Technology

Address:

971 Burke Road Camberwell VIC Australia 3124

Phone:

61 3 9095 3036

MD, CEO & Exec. Director:

Mr. Robert Read BComm(Mgt), BA(Psych), GAICD

Founder, Chief Product Officer & Exec. Director:

Mr. Joshua Swinnerton MEI, GradCert Eng., BE, BCS(Hons).

Company Sec.:

Mr. Carlo Campiciano

Chief Financial Officer:

Mr. Simon Glover

Interim Chief Technology Officer:

Mr. Craig Schnuriger

Company Overview:

MedAdvisor Limited develops and delivers software for personal medication management in Australia. It develops and deploys the MedAdvisor, a medication and adherence platform that connects health professionals with patients using mobile and Web technologies; and PlusOne, a software platform, which allows pharmacies to connect with patients via SMS, App, and Web/email. MedAdvisor Limited was incorporated in 2010 and is based in Camberwell, Australia.

MDR Share Price Information

Shares Issued:

246.72M

Market Capitalisation:

$115.96M

Revenue (TTM):

$8.80M

Revenue Per Share (TTM):

$0.04

Earnings per Share:

$-0.006

Profit Margin:

-1.0137

Operating Margin (TTM):

$-1.02

Return On Assets (TTM):

$-0.28

Return On Equity (TTM):

$-0.55

Quarterly Revenue Growth (YOY):

0.144

Gross Profit(TTM):

$-1,784,511

Diluted Earnings Per Share (TTM):

$-0.043

MDR CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-103,890

Change To Liabilities:

$0.92M

Total Cashflow From Investing Activities:

$-103,890

Net Income:

$-8,101,385

Total Cash From Operating Activities:

$-6,945,168

Depreciation:

$110.62K

Change To Account Receivables:

$-234,734

Capital Expenditures:

$103.89K

MDR Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-8,101,385

Net Income:

$-8,101,385

Gross Profit:

$7.23M

Operating Income:

$-9,036,177

Other Operating Expenses:

$784.96K

Interest Expense:

$16.33K

Total Revenue:

$8.24M

Total Operating Expenses:

$16.26M

Cost Of Revenue:

$1.01M

MDR Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$1.17M

Total Liabilities:

$3.13M

Total Stockholder Equity:

$8.64M

Other Current Liabilities:

$1

Total Assets:

$11.77M

Common Stock:

$28.14M

Other Current Assets:

$127.02K

Retained Earnings:

$-20,645,126

Other Liabilities:

$53K

Good Will:

$4.01M

Other Assets:

$250K

Cash:

$4.40M

Total Current Liabilities:

$3.08M

Property - Plant & Equipment:

$405.30K

Net Tangible Assets:

$3.46M

Total Current Assets:

$5.94M

Net Receivables:

$1.13M

Short-Term Investments:

$5.84M

Accounts Payable:

$746.62K

Non Currrent Assets (Other):

$5.84M

Short-Term Investments:

$5.84

Non Current Liabilities Total:

$53K

MDR Share Price History

MDR News

19 May, 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
21 Mar, 2020
Robert Read has been the CEO of MedAdvisor Limited (ASX:MDR) since 2015. First, this article will compare CEO...
21 Jan, 2020
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
15 Nov, 2019
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
06 Oct, 2019
HMS Holdings Corp. (HMSY), a leading U.S.-based provider of healthcare technology, analytics and engagement solutions, today announced that HMS, through a subsidiary, will make a strategic investment of $7.5 million (US) in ordinary shares of MedAdvisor Limited (ASX:MDR), Australia’s leading digital medication management company.  HMS intends to fund the investment with cash on hand. Upon completion of the transaction, HMS will hold an approximate 13% ownership stake in MedAdvisor.
01 Oct, 2019
In 2015 Robert Read was appointed CEO of MedAdvisor Limited (ASX:MDR). This report will, first, examine the CEO...